Bayesian Design of Proof-of-Concept Trials

Therapeutic Innovation and Regulatory Science

Volumn 49, Issue 1, 2015, Pages 155-162

  Fisch, Roland ^a   Jones, Ieuan ^a   Jones, Julie ^a   Kerman, Jouni ^a   Rosenkranz, Gerd Karl ^a   Schmidli, Heinz ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bayesian inference; clinical trials; decision criteria; operating characteristics; phase IIa; proof of concept

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; HUMAN; PRIORITY JOURNAL; PROOF OF CONCEPT; PSORIASIS; QUANTITATIVE ANALYSIS; STUDY DESIGN;

EID: 84920984862     PISSN: 21684790     EISSN: 21684804     Source Type: Journal    
DOI: 10.1177/2168479014533970     Document Type: Article

References (22)

1. Sheiner LB.Learning versus confirming in clinical drug development.Clin Pharmacol Ther. 1997;61 (3): 275-291
2. Cartwright ME,Cohen S,Fleishaker JC, et al.Proof of concept: a PhRMA position paper with recommendations for best practice.Clin Pharmacol Ther. 2010;87 (3): 278-285
3. DiMasi JA,Feldman L,Seckler A,Wilson A.Trends in risks associated with new drug development: success rates for investigational drugs.Clin Pharmacol Ther. 2010;87 (3): 272-277
4. Mallinckrodt C,Molenberghs G,Persinger C,Ruberg S,Sashegyi A,Lindborg S.A portfolio-based approach to optimize proof-of-concept clinical trials.J Biopharm Stat. 2012;22 (3): 596-607
5. Neuenschwander B,Rouyrre N,Hollaender N,Zuber E,Branson M.A proof of concept phase II non-inferiority criterion.Stat Med. 2011;30 (13): 1618-1627
6. Chuang-Stein C,Kirby S,Hirsch I,Atkinson G.The role of the minimum clinically important difference and its impact on designing a trial.Biopharm Stat. 2011;10 (3): 250-256
7. Chuang-Stein C,Kirby S,French J, et al.A quantitative approach for making go/no-go decisions in drug development.Drug Inf J. 2011;45:187-202
8. Spiegelhalter DJ,Freedman LS,Parmar MKB.Applying Bayesian ideas in drug development and clinical trials.Stat Med. 1993;12 ((15-16)): 1501-1511
9. Spiegelhalter DJ,Abrams KR,Myles JPBayesian Approaches to Clinical Trials and Health Care Evaluation. New York, NY: John Wiley & Sons; 2004:
10. Hobbs BP,Carlin BP.Practical Bayesian design and analysis for drug and device clinical trials.J Biopharm Stat. 2007;18:54-80
11. Berry SM,Carlin BP,Lee JJ,Müller PBayesian Adaptive Methods for Clinical Trials. London, UK: Chapman & Hall/CRC; 2010:
12. Gelfand AE,Smith AFM.Sampling-based approaches to calculating marginal densities.J Am Stat Assoc. 1990;85:398-409
13. Neuenschwander B,Capkun-Niggli G,Branson M,Spiegelhalter DJ.Summarizing historical information on controls in clinical trials.Clin Trials. 2010;7 (1): 5-18
14. Gsteiger S,Neuenschwander B,Mercier F,Schmidli H.Using historical control information for the design and analysis of clinical trials with overdispersed count data.Stat Med. 2013;32 (21): 3609-3622
15. Bansback N,Sizto S,Sun H,Feldman S,Willian MK,Anis A.Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.Dermatology. 2009;219 (3): 209-218
16. Kieser M,Hauschke D.Assessment of clinical relevance by considering point estimates and associated confidence intervals.Biopharm Stat. 2005;4 (2): 101-107
17. Smith MK,Jones I,Morris MF,Grieve AP,Tan K.Implementation of a Bayesian adaptive design in a proof of concept study.Biopharm Stat. 2006;5:39-50
18. Gsponer T,Gerber F,Bornkamp B,Ohlssen D,Vandemeulebroecke M,Schmidli H.A practical guide to Bayesian group sequential designs.Biopharm Stat. 2014;13 (1): 71-80
19. Gerber F,Gsponer T.gsbDesign: an R Package for evaluating operating characteristics for a group sequential Bayesian design. submitted to.J Stat Softw. 2014;:
20. Dmitrienko A,Wang M-D.Bayesian predictive approach to interim monitoring in clinical trials.Stat Med. 2006;25:2178-2195
21. Baeten D,Baraliakos X,Braun J, et al.Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.Lancet. 2013;382 (9906): 1705-1713
22. Hueber W,Sands BE,Lewitzky S, et al.Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial.Gut. 2012;61 (12): 1693-700